Genzyme Renagel Trial Will Compare Effect On Mortality With Other Agents
Executive Summary
Genzyme is studying Renagel's effect on cardiac calcification and mortality to support a comparative claim versus other phosphate binders, Genzyme Senior VP-Corporate Affairs Elliott Hillback told the Bear Stearns "virtual" healthcare conference Sept. 24.